CJC-1295 with DAC

Know your compound

What is CJC-1295 with DAC?

CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) that enables covalent binding to serum albumin. The albumin-binding mechanism extends circulating half-life from minutes — characteristic of native GHRH — to approximately 8 days, producing sustained plasma exposure in preclinical models.

Research interest centres on the compound's capacity to maintain stable GH and IGF-1 serum concentrations across multi-day windows rather than the pulsatile pattern seen with unmodified GHRH analogues. That tonic elevation profile makes it a useful tool for investigating chronic GH/IGF-1 signalling without repeated dosing intervals, as documented in clinical pharmacokinetic work by Teichman et al.

• GH and IGF-1 elevation sustained for up to 8 days post-dose in clinical pharmacokinetic studies (Teichman et al.)
• Albumin-binding DAC modification confirmed as the mechanism of half-life extension
• Stable multi-week serum concentrations documented, supporting chronic GH-axis exposure models